Samyang Biopharm삼양바이오팜
0120G0 · KOSPI · ₩0120G0 · 삼양바이오팜
₩42,300▼ ₩1,200 (2.76%)End-of-day · Oct 26, 2026 · End-of-day prices.
Income statement
| 2025 | |
|---|---|
| Revenue | ₩29B |
| Cost of sales | ₩14B |
| Gross profit | ₩15B |
| Operating income | ₩2.7B |
| Net income | ₩2.2B |
| Net income to shareholders | ₩2.2B |
Balance sheet
| 2025 | |
|---|---|
| Total assets | ₩339B |
| Current assets | ₩171B |
| Cash and equivalents | ₩30B |
| Total liabilities | ₩105B |
| Current liabilities | ₩102B |
| Borrowings | ₩78B |
| Total equity | ₩235B |
| Shareholders' equity | ₩235B |
Cash flow
| 2025 | |
|---|---|
| Cash from operations | ₩9.8B |
| Capital spending | ₩6.7B |
| Free cash flow | ₩3B |
Consolidated where available. Amounts in won.
Also known as: Samyang Biopharm / 삼양바이오팜 / 0120G0 / KRX:0120G0
Source: KRX statistical information